Gen-AI Designed Enzymes for Pharmaceutical Innovation
Public company, workplace, funding, and market signals
Pando Bioscience is a Boston-area AI-driven synthetic biology company that engineers industrial-grade enzymes for pharma, diagnostics, and life-science tools using proprietary ultra-high-throughput wet-lab screening plus ML. Public sources conflict slightly on founding year (YC says 2022; LinkedIn shows 2023), so the company appears to have launched in YC W23 and is headquartered in Watertown, MA. No public GitHub or X profile was found.
Primary product
Proprietary engineered enzymes, especially Phi29-like polymerases (Saiyan-Phi29, PD-Phi29) and custom enzyme-development services
Founded
2022
Headquarters
134 Coolidge Avenue, Watertown, Massachusetts 02472, United States
Team size
1-10
Work style
Onsite
Industry
Biotechnology Research
Sub-industry
0 jobs at Pando Bioscience
Check back later for new openings
Synthetic biology / enzyme engineering
Offices
Business model
Stage
Pre-Seed
Total raised
$500K
Latest round
Pre-Seed · Apr 2023
Latest amount
$500K
Apr 2023 · Y Combinator
Investors
Hands-on, science-heavy, fast-paced, and collaborative; the team blends wet-lab scientists and machine-learning engineers and emphasizes rapid enzyme discovery and validation.
Work style
Onsite
Pricing
Quote-based B2B pricing for custom R&D projects plus direct sale/distribution of proprietary enzymes; no public pricing found.
Differentiators
Technology
Customers
Competitors
Estimated revenue
about $1M ARR (2024 estimate)
Estimated monthly visits
1.1K
Traffic estimate as of Feb 2025